SONOMA PHARMACEUTICALS INC (SNOA) Stock Price, Quote, News and Overview
NASDAQ:SNOA - Nasdaq - US83558L3033 - Common Stock - Currency: USD
SNOA Quote, Performance and Key Statistics
2.395
-0.02 (-1.03%)
The current stock price of SNOA is 2.395 USD. In the past month the price decreased by -9.28%. In the past year, price decreased by -17.98%.
SNOA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About SNOA
Company Profile
Sonoma Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Boulder, Colorado and currently employs 172 full-time employees. The company went IPO on 2007-01-26. Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The firm's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
Company Info
SONOMA PHARMACEUTICALS INC
5445 Conestoga Court, Suite 150
Boulder COLORADO 30189 US
CEO: Amy Trombly
Employees: 10
Company Website: https://sonomapharma.com/
Investor Relations: http://ir.oculusis.com/
Phone: 18007599305
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What is the stock price of SONOMA PHARMACEUTICALS INC today?
The current stock price of SNOA is 2.395 USD. The price decreased by -1.03% in the last trading session.
What is the ticker symbol for SONOMA PHARMACEUTICALS INC stock?
The exchange symbol of SONOMA PHARMACEUTICALS INC is SNOA and it is listed on the Nasdaq exchange.
On which exchange is SNOA stock listed?
SNOA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SONOMA PHARMACEUTICALS INC stock?
7 analysts have analysed SNOA and the average price target is 17.34 USD. This implies a price increase of 624.01% is expected in the next year compared to the current price of 2.395. Check the SONOMA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SONOMA PHARMACEUTICALS INC worth?
SONOMA PHARMACEUTICALS INC (SNOA) has a market capitalization of 3.88M USD. This makes SNOA a Nano Cap stock.
How many employees does SONOMA PHARMACEUTICALS INC have?
SONOMA PHARMACEUTICALS INC (SNOA) currently has 10 employees.
What are the support and resistance levels for SONOMA PHARMACEUTICALS INC (SNOA) stock?
SONOMA PHARMACEUTICALS INC (SNOA) has a resistance level at 2.61. Check the full technical report for a detailed analysis of SNOA support and resistance levels.
Is SONOMA PHARMACEUTICALS INC (SNOA) expected to grow?
The Revenue of SONOMA PHARMACEUTICALS INC (SNOA) is expected to grow by 5.59% in the next year. Check the estimates tab for more information on the SNOA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SONOMA PHARMACEUTICALS INC (SNOA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNOA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNOA, evaluating the profitability, health, valuation and growth aspects
- SONOMA PHARMACEUTICALS INC (SNOA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SONOMA PHARMACEUTICALS INC (SNOA) Sales and EPS estimates to see what analysts future expectations are.
- SONOMA PHARMACEUTICALS INC (SNOA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SONOMA PHARMACEUTICALS INC (SNOA) Insider and Institutional Ownership to learn about the owners and their transactions.
- SONOMA PHARMACEUTICALS INC (SNOA) Stock Chart to make your own analysis
- SONOMA PHARMACEUTICALS INC (SNOA) Latest news and press-releases to stay up to date.
Does SONOMA PHARMACEUTICALS INC (SNOA) stock pay dividends?
SNOA does not pay a dividend.
When does SONOMA PHARMACEUTICALS INC (SNOA) report earnings?
SONOMA PHARMACEUTICALS INC (SNOA) will report earnings on 2025-06-16, after the market close.
What is the Price/Earnings (PE) ratio of SONOMA PHARMACEUTICALS INC (SNOA)?
SONOMA PHARMACEUTICALS INC (SNOA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.96).
What is the Short Interest ratio of SONOMA PHARMACEUTICALS INC (SNOA) stock?
The outstanding short interest for SONOMA PHARMACEUTICALS INC (SNOA) is 2.61% of its float. Check the ownership tab for more information on the SNOA short interest.
SNOA Technical Analysis
SNOA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNOA. No worries on liquidiy or solvency for SNOA as it has an excellent financial health rating, but there are worries on the profitability.
SNOA Financial Highlights
Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -3.96. The EPS decreased by -59.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.42% | ||
| ROE | -76.96% | ||
| Debt/Equity | 0 |
SNOA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to SNOA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 24.72% and a revenue growth 5.59% for SNOA